CAS 18417-89-5|Sangivamycin
| Common Name | Sangivamycin | ||
|---|---|---|---|
| CAS Number | 18417-89-5 | Molecular Weight | 309.28 |
| Density | / | Boiling Point | 880.6ºC at 760 mmHg |
| Molecular Formula | C12H15N5O5 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | 486.4ºC |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | sangivamycin |
|---|---|
| Synonym | More Synonyms |
Sangivamycin BiologicalActivity
| Description | Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2]. |
|---|---|
| Related Catalog | Signaling Pathways >>Epigenetics >>PKCResearch Areas >>CancerSignaling Pathways >>Cell Cycle/DNA Damage >>Nucleoside Antimetabolite/AnalogSignaling Pathways >>TGF-beta/Smad >>PKC |
| In Vitro | Sangivamycin has differential antitumor effects in drug-sensitive MCF7/wild type (WT) cells, causing growth arrest, and in multidrug-resistant MCF7/adriamycin-resistant (ADR) human breast carcinoma cells, causing massive apoptotic cell death[2]. Sangivamycin (0.3 μM; 0-72 hours), shows almost maximal cytocidal (for MCF7/ADR) or cytostatic (for MCF7/WT) effects[2]. Sangivamycin activates caspases in MCF7/ADR cells. Upon exposure of MCF7/ADR cells to Sangivamycin (0.3 μM;), a vast amount of cleavage of lamin A to a 28-kDa fragment is detected within 48 hours[2]. |
| References | [1]. Loomis CR, Bell RM. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem. 1988;263(4):1682-1692. [2]. Lee SA, et al. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. J Biol Chem. 2007;282(20):15271-15283. |
Chemical & Physical Properties
| Boiling Point | 880.6ºC at 760 mmHg |
|---|---|
| Molecular Formula | C12H15N5O5 |
| Molecular Weight | 309.28 |
| Flash Point | 486.4ºC |
| Exact Mass | 327.11800 |
| PSA | 178.97000 |
| Vapour Pressure | 3.3E-33mmHg at 25°C |
| InChIKey | OBZJZDHRXBKKTJ-JTFADIMSSA-N |
| SMILES | NC(=O)c1cn(C2OC(CO)C(O)C2O)c2ncnc(N)c12 |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1200 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 11 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 4 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 5 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
MUTATION DATA - TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Rodent - mouse Cells - not otherwise specified
- DOSE/DURATION :
- 500 nmol/L
- REFERENCE :
- CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 41,1784,1981
- TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Rodent - mouse Cells - not otherwise specified
- DOSE/DURATION :
- 500 nmol/L
- REFERENCE :
- CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 41,1784,1981
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300-H310-H330 |
| Precautionary Statements | P260-P264-P280-P284-P302 + P350-P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | T+ |
| Risk Phrases | 26/27/28 |
| RIDADR | UN 2811 6.1/PG 2 |
| RTECS | UY9355000 |
Articles28
More Articles| Synthesis and in vitro antitumor activity of some amino-deoxy 7-hexofuranosylpyrrolo[2,3-d]pyrimidines. Carbohydr. Res. 308(3-4) , 319-28, (1998) 7-(6-amino-6-deoxy-beta-D-glucofuranosyl)-5-cyanopyrrolo[2,3 -d]pyrimidine (22) and 7-(3-amino-methyl-3-deoxy-beta-D-allofuranosyl)-5- cyanopyrrolo[2,3-d]pyrimidine (28) were synthesized by sequential... | |
| Kinetics and localization of the phosphorylation of rhodopsin by protein kinase C. J. Biol. Chem. 270(12) , 6710-7, (1995) Protein kinase C isolated from retina catalyzes the stoichiometric phosphorylation of bovine rhodopsin. Enzymological studies using receptor in rod outer segment membranes stripped of peripheral prote... | |
| Synthesis of pyrrolo[2,1-f][1,2,4]triazine C-nucleosides. Isosteres of sangivamycin, tubercidin, and toyocamycin. Carbohydr. Res. 331(1) , 77-82, (2001) Syntheses of pyrrolo[2,1-f][1,2,4]triazine C-nucleosides are reported. Treatment of pyranulose glycoside with aminoguanidine in acetic acid gave the corresponding semicarbazone in 96% yield. The ring ... |
Synonyms
| 7-Carboxamido-7-deazaadenosine |
| 7-DEAZA-7-CARBAMOYLADENOSINE |
| 7-DEAZAADENOSINE-7-CARBOXAMIDE |
| SANGIVAMYCIN |
